Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity

INTRODUCTION: The US Food and Drug Administration approved a 23 mg daily dose of donepezil for treatment of moderate to severe Alzheimer's disease (AD) based on outcomes from a large trial comparing the 23 mg/day dose with the standard 10 mg/day dose. Results from this study indicated that afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferris, Steven, Cummings, Jeffrey, Christensen, Daniel, Doody, Rachelle, Farlow, Martin, Sabbagh, Marwan, Liu, Liang, Mackell, Joan, Fain, Randi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055003/
https://www.ncbi.nlm.nih.gov/pubmed/23433097
http://dx.doi.org/10.1186/alzrt166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055003/
https://www.ncbi.nlm.nih.gov/pubmed/23433097
http://dx.doi.org/10.1186/alzrt166

Ejemplares similares